Abstract: The present invention relates to an improved composition of copolymer-1 comprising copolymer-1 substantially free of species having a molecular weight of over 40 kilodaltons.

Abstract: The present invention relates to an improved composition of copolymer-1 comprising copolymer-1 substantially free of species having a molecular weight of over 40 kilodaltons.

Abstract: The present invention relates to the treatment of multiple sclerosis by ingestion or inhalation of copolymet-1 and pharmaceutical compositions useful for such treatment.

Abstract: Peptides having at least nine amino acid residues each including an amino acid sequence which corresponds to position p200-208 or p262-266 of the human acetylcholine receptor .alpha.-subunit, but differing therefrom by one or more amino acid substitutions, are disclosed. These peptides inhibit the proliferative response of human peripheral blood lymphocytes to the myasthenogenic peptides p195-212 and p259-271 and are suitable for treatment of subjects afflicted with myasthenia gravis.

Abstract: The present invention relates to an improved composition of copolymer-1 comprising copolymer-1 substantially free of species having a molecular weight of over 40 kilodaltons.

Abstract: The present invention relates to an improved composition of copolymer-1 comprising copolymer-1 substantially free of species having a molecular weight of over 40 kilodaltons.

Abstract: The present invention relates to an improved composition of copolymer-1 comprising copolymer-1 substantially free of species having a molecular weight of over 40 kilodaltons.

Abstract: Pharmaceutical compositions comprising as active ingredient a synthetic random copolymer of average molecular weight of about 4,000-12,000, preferably 6,000-8,000, said copolymer consisting of glutamic acid (Glu), lysine (Lys), alanine (Ala) and tyrosine (Tyr) residues in a relative molar ratio of 1.4-2.1 parts of Glu to 3.2-4.4 parts of Lys to 4.0-6.0 parts of Ala to 1.0 parts of Tyr (herein GLAT copolymers), can be used in a method for prevention and treatment of graft-versus-host disease in patients in the course of bone marrow and organ transplantation.

Abstract: The present invention relates to an improved composition of copolymer-1 comprising copolymer-1 substantially free of species having a molecular weight of over 40 kilodaltons.

Abstract: A synthetic vaccine against cholera and against heat-labile toxin of E. coli comprising a conjugate of a high-molecular weight carrier with a synthetic polypeptide corresponding to part of the sequence of Subunit B of natural cholera toxin. The sequences of choice are those corresponding to sequences 45 to 64, 50 to 64 and 8 to 20 of Subunit B, or slightly modified sequences, similar to the above.

Abstract: A polymer of peptidic type formed by a chain formed from aminoacyl residues preferably derived of at least one of the amino-acid residues selected from the class consisting of .alpha.,.gamma.-diaminobutyric acid, ornithine, lysine, homo-lysine, of which the lateral amino functions portionally carry peptide branches of which the aminoacyl residues are preferably derived of those selected from the class consisting of alanine, glycine, .alpha.-aminobutyric acid, valine, leucine and proline, the above-said peptide polymer having an average molecular weight comprised between about 50,000 and 250,000, and to which are bound covalently, muramyl-peptide units of which the two first aminoacid residues bound to the muramyl group are stereoisomers of the D series, the second aminoacid residue having the structure of the glutamic acid.This product is useful as anti-infectious agent.

Abstract: Novel pharmaceutically active compositions of matter comprise in combination a low-molecular-weight anti-cancer drug chemically linked to antibodies selective or specific to tumor antigens. The preferred linkage is via covalent bonds, whether directly or via a linking agent. A method of treatment of mammals afflicted with malignant growth comprises administering a pharmaceutical composition of matter defined above.

Abstract: Chemotherapeutic agents comprising an antigen binding dimer derived from an immunoglobulin covalently bound to a drug are disclosed. The dimer and drug are bound, while preserving both the antibody activity of the dimer and the pharmacological activity of the drug.

Abstract: A novel synthetic peptide corresponding to the eleven amino acid residues of the NH.sub.2 -terminal portion in the sequence of carcinoembrionic antigen (CEA) has been synthesized and this was attached by means of a water-soluble carbodiimide reagent to multichain poly(DL)-alanine as well as to bovine serum albumin. The resulting macromolecular conjugates provoked rabbit anti- CEA(1-11) peptide antibodies and a novel assay was developed for ascertaining the presence of adenocarcinomas of the digestive tract, pancreas and breast, based on said novel compositions of matter.